Following Monday’s biennial analyst meeting, SunTrust raised its price target on Medtronic plc MDT to $98 from $93.
Indicating a bullish outlook on their diabetes segment, the analysts believe it's possible for management to hit their projections for double-digit growth in their diabetes franchise. SunTrust believes a focus on type 2 diabetes treatment will pay off, as 90 percent of the diabetic population is diagnosed with type 2.
Also mentioned is a projected FY2021 cash balance of $28 billion, which SunTrust believes could be used to make deals or buy back shares.
Medtronic shares were flat in Monday’s trading session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.